These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33480841)

  • 1. Population pharmacokinetics of meropenem among post-operative patients in Pakistan.
    Zaman M; Khan HM; Usman M; Khokhar MI; Rasheed H; Abbas M; Khan RR; Saleem R
    Int J Clin Pharmacol Ther; 2021 May; 59(5):398-408. PubMed ID: 33480841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
    Usman M; Frey OR; Hempel G
    Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of meropenem dosage in the critically ill population based on renal function.
    Crandon JL; Ariano RE; Zelenitsky SA; Nicasio AM; Kuti JL; Nicolau DP
    Intensive Care Med; 2011 Apr; 37(4):632-8. PubMed ID: 21136037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ciprofloxacin in Pakistani patients suffering from enteric fever.
    Saleem R; Khan HM; Usman M; Khokhar MI; Rasheed H; Abbas M; Khan RR; Zaman M; Maqsood Z
    Int J Clin Pharmacol Ther; 2021 Jan; 59(1):47-54. PubMed ID: 33026316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
    Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
    Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan.
    Munir MM; Rasheed H; Khokhar MI; Khan RR; Saeed HA; Abbas M; Ali M; Bilal R; Nawaz HA; Khan AM; Qamar S; Anjum SM; Usman M
    Front Pharmacol; 2021; 12():721819. PubMed ID: 34858169
    [No Abstract]   [Full Text] [Related]  

  • 8. The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis.
    Abulfathi AA; de Jager V; van Brakel E; Reuter H; Gupte N; Vanker N; Barnes GL; Nuermberger E; Dorman SE; Diacon AH; Dooley KE; Svensson EM
    Front Pharmacol; 2021; 12():637618. PubMed ID: 34267655
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of meropenem in critically ill infant patients.
    Yonwises W; Wacharachaisurapol N; Anugulruengkitt S; Maimongkol P; Treyaprasert W
    Int J Infect Dis; 2021 Oct; 111():58-64. PubMed ID: 34419581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models.
    Dhaese SAM; Farkas A; Colin P; Lipman J; Stove V; Verstraete AG; Roberts JA; De Waele JJ
    J Antimicrob Chemother; 2019 Feb; 74(2):432-441. PubMed ID: 30376103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
    Selig DJ; Reed T; Chung KK; Kress AT; Stewart IJ; DeLuca JP
    Blood Purif; 2023; 52(1):25-31. PubMed ID: 35526522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.